The Shrinking Value of Best-In-Class & First-In-Class Drugs. (cover story)

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Subject Terms:
      BRISTOL-Myers Squibb Co. 001288497 BMY; REGENERON Pharmaceuticals Inc. 194873139 REGN; SANOFI SA
    • Abstract:
      The article discusses the shrinking value of best-in-class and first-in-class drugs as of July 2015. It mentions UCB Group's Cimzia (Certolizumab) and Orencia (abatacept) from Bristol-Myers Squibb Co. The market dominance of the drug Humira (aldalimubab) from Abbvie Inc. is highlighted. The possible launch of alirocumab and Amgen (evolocumab), the first two drugs under the partnership of Regeneron Pharmaceuticals Inc. and Sanofi, in July or August is also mentioned.
HoldingsOnline